Kelun-Biotech's Sac-TMT Secures Third Marketing Approval in NSCLC Treatment Sichuan Kelun-Biotech's TROP2 ADC Sac-TMT has received NMPA approval for its third indication, targeting EGFRm NSCLC after TKI therapy.

Kelun-Biotech's Sac-TMT Secures Third Marketing Approval in NSCLC Treatment #China #Chengdu #Kelun-Biotech #TROP2_ADC #Sac-TMT

Promising Outcomes from Kelun-Biotech's Innovative Cancer Treatment Sacituzumab Tirumotecan Recent findings from Kelun-Biotech's research on sacituzumab tirumotecan reveal encouraging results for cancer patients resistant to standard treatments.

Promising Outcomes from Kelun-Biotech's Innovative Cancer Treatment Sacituzumab Tirumotecan #China #Chengdu #Kelun-Biotech #TROP2_ADC #sacituzumab_tirumotecan

Kelun-Biotech Unveils Clinical Research Breakthroughs at 2025 ASCO Annual Meeting The 2025 ASCO Annual Meeting will showcase significant findings from Kelun-Biotech's clinical studies, highlighting major advancements in cancer treatment, including novel therapies for NSCLC and triple-negative breast cancer.

Kelun-Biotech Unveils Clinical Research Breakthroughs at 2025 ASCO Annual Meeting #USA #Chicago #Kelun-Biotech #TROP2_ADC #Sac-TMT

Breakthrough Results for Kelun-Biotech's Sacituzumab Tirumotecan in Top Medical Journal Sichuan Kelun-Biotech announces significant findings on sacituzumab tirumotecan (sac-TMT), published in Nature Medicine, marking a major advancement for cancer treatment.

Breakthrough Results for Kelun-Biotech's Sacituzumab Tirumotecan in Top Medical Journal #China #Chengdu #Kelun-Biotech #Sacituzumab #TROP2_ADC

Sichuan Kelun-Biotech Reports 2024 Annual Results: Significant Gains in R&D and Profitability Sichuan Kelun-Biotech recently unveiled its annual results for 2024, highlighting a remarkable 68% surge in gross profit amid evolving challenges in the biopharmaceutical landscape.

Sichuan Kelun-Biotech Reports 2024 Annual Results: Significant Gains in R&D and Profitability #China #Chengdu #biotechnology #Kelun-Biotech #TROP2_ADC

Illuminating Findings from Kelun-Biotech's TROP2 ADC at the 2025 ASCO GU Symposium Explore groundbreaking efficacy and safety results of sacituzumab tirumotecan, presented by Kelun-Biotech at the ASCO GU Cancers Symposium in 2025.

Illuminating Findings from Kelun-Biotech's TROP2 ADC at the 2025 ASCO GU Symposium #USA #San_Francisco #Kelun-Biotech #TROP2_ADC #sacituzumab_tirumotecan